Adiponectin Gene Polymorphisms and Possible Susceptibility to Metabolic Syndrome among the Sudanese Population: A Case-Control Study

Mosad, Altaf S.; Elfadil, Ghada A.; Gassoum, Alsadig; Elamin, Khanssa M.; Husain, Nazik Elmalaika Obaid Seid Ahmed

doi:https://doi.org/10.1155/2023/5527963

International Journal of Endocrinology

On this page

Abstract Introduction Results Discussion Data Availability Ethical Approval Conflicts of Interest Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2023 | Article ID 5527963 | https://doi.org/10.1155/2023/5527963

Adiponectin Gene Polymorphisms and Possible Susceptibility to Metabolic Syndrome among the Sudanese Population: A Case-Control Study

Altaf S. Mosad,¹Ghada A. Elfadil,¹Alsadig Gassoum,²Khanssa M. Elamin,³and Nazik Elmalaika Obaid Seid Ahmed Husain⁴

Academic Editor: Shyamsundar Pal China

Received15 Dec 2022

Revised08 Mar 2023

Accepted18 Apr 2023

Published27 Apr 2023

Abstract

Background and Aim. The adiponectin gene (ADIPQ) has been identified as a human adiposity marker of metabolic syndrome (MetS) in several ethnic cultures. This study aimed to determine the allelic genotypes and haplotypes distribution of the ADIPQ gene polymorphisms and its association with body mass index (BMI), waist circumference (WC), glycated hemoglobin (HbA1c), and lipid profile in MetS adult Sudanese patients. Methodology. Four hundred and twenty middle-aged adults participated in this community-based case-control research. BMI (kg/m²) and blood pressure (BP) were measured. HbA1c (%) and lipid profile evaluation was performed on fasting blood samples. The guanidine extraction procedure was used to extract genomic DNA from EDTA whole blood by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP); samples were genotyped for the polymorphisms (rs266729), (rs2241766), and (rs1501299). Results. There is a significant difference in genotypic frequencies of the rs266729, rs2241766, and rs1501299 SNPs and allele frequencies between the MetS patients and non-MetS group. MetS patients had a significantly higher serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein-cholesterol (LDL-C) in the GG genotype of rs2241766 . Additionally; the TT genotype of rs1501299 had higher SBP, serum TG, TC, and LDL-C . Multivariate logistic regression analysis showed hypertension, hyperglycemia, BMI, WC, serum TG, ADIPOQ rs2241766 (TG allele), and ADIPOQ rs1501299 (GT allele) had independently predicted the incidence of metabolic syndrome in the Sudanese population. The three investigated SNPs of ADIPOQ were in a moderate linkage disequilibrium (LD) connection according to the LD measures (D' = 0.54, 0.62, and 0.69, respectively). The CTT, CGG, and GTG haplotypes, which consist of three alleles of −11377C > G, +45T > G, and +276G > T, were shown to report 1.788-, 1.622,- and 1.641-fold risks toward MetS susceptibility in Sudanese’s population, respectively. Conclusion. Along with clinical and biochemical signs, the ADIPOQ gene’s genetic variants (rs266729, rs2241766, and rs1501299), CTT, CGG, and GTG haplotypes are connected to the MetS risk among the Sudanese population.

1. Introduction

The most recent pandemic of disorders that has affected humans is metabolic syndrome (MetS). Since obesity and type 2 diabetes (T2D) are included in the MetS category, it has ensnared millions worldwide [1, 2]. MetS, as determined by the Adult Treatment Panel III criteria of the National Cholesterol Education Program (NCEP ATP III), was identified when at least three of the following factors were present: abdominal obesity (WC ≥ 102 cm, ≥88 cm in men and women, respectively), elevated TG (≥150 mg/dL), reduced HDL-C (<40 mg/dL, <50 mg/dL in men and women), increased blood pressure (≥130/85 mmHg), and elevated fasting plasma glucose (≥110 mg/dL) [3, 4]. MetS was present in 16.6% of the Sudanese population [4]. Because of the increased frequency of MetS and its impact on public health, early detection and management of MetS are crucial to preventing the onset of T2D, cardiovascular disease, and other consequences.

The ADIPOQ gene, situated on chromosome 3q27 [5, 6] and only expressed in human adipose tissue, is responsible for producing the plasma protein adiponectin [7, 8]. T2D, obesity, and metabolic syndrome have all been linked to the 3q27 gene [9, 10]. Numerous researchers have looked into the adiponectin gene area in various populations to find genetic variations that substantially influence the pathophysiology of obesity, metabolic syndrome (MetS), diabetes, and related complications [11].

Three exons make up the ADIPOQ obesity-associated variants, and the rs2241766, rs266729, and rs1501299 were frequently studied [8]. The minor allele G of the SNP rs266729, which is situated in the gene’s promoter region, changes the sequence of the binding site (SP1), resulting in a loss of the SP1 binding effect and perhaps reducing the transcription activity of the adiponectin promoter [10]. The SNP rs2241766, found in exon 2 of the gene, may have polymorphic effects on the stability or shearing of precursor mRNA or the level of proteins. The ADIPOQ gene’s second intron has the SNP rs1501299 and studies suggest that this polymorphism may impact how well the exon next to it functions [9]. The polymorphism of these two locations influences the body’s insulin sensitivity and stimulates the development of T2D [9]. Therefore, this study aimed to ascertain the genotypes, haplotypes, and allelic distribution of the ADIPQ gene polymorphisms (rs266729, rs2241766, and rs1501299) and its relationship to MetS in Sudanese population. Additionally, ADIPQ gene SNPs based on BMI, HbA1c, and the lipid profile in the Sudanese people are investigated.

2. Methodology

Four hundred and twenty middle-aged adult Sudanese participants (210 had MetS and 210 non-MetS) were recruited for this community-based case-control study between July 2019 and July 2021. After getting ethical approval from the Research Committee of the Sudan University of Science and Technology (DSR-IEC-04-08), all participants received written informed consent forms after being told of the study’s purpose. Patients with liver illness, renal failure, autoimmune disorders, and corticosteroid medication and patients with incompletely documented data were excluded from this study based on their medical records. Participants were divided into two groups (MetS and non-MetS), matched according to age and gender and based on whether they had MetS, as determined by the NCEP ATP III criteria.

2.1. Data Collection and Analysis

Patients' weights were measured using a weight balance, their heights were measured using a meter, and their waists were measured using stretch-resistant tape between the bottom edge of the lower rib and the iliac crest. A mercury sphygmomanometer was used to check the patient’s blood pressure (SBP and DBP). Five milliliters of fasting venous blood was drawn in the morning and divided into two containers: a whole blood container (EDTA) for HbA1c measurement and DNA extraction and a plain container for serum TG, TC, LDL-C, and HDL-C measurements. Automated spectrophotometers (Mindray-BA-88A) and ichroma (Boditech-I-CHROMA Reader) were used to measure serum TG, TC, LDL-C, HDL-C, and HbA1c, respectively. BMI was calculated by dividing body weight/kg by height/m² [12].

2.2. DNA Extraction

Genomic DNA was extracted from whole blood using a guanidine extraction protocol [13]. The quality of DNA was assessed using 2.0% gel electrophoresis.

2.3. Screening of ADIPOQ SNPs

PCR-RFLP was used to amplify and genotype ADIPOQ variants −11377C/G (rs266729), +45T/G (rs2241766), and +276G/T (rs1501299). The amount of the PCR reaction mixture was 20 μL, and the annealing temperatures varied depending on the primers (Table 1). A 2.0% agarose gel stained with ethidium bromide was used to test the amplified products for electrophoresis. Table 1 shows the specification of the restriction enzymes used in this study, obtained from Fermentas, Thermo Fisher Scientific Inc., USA. Following the manufacturer’s recommendations, 1U of the relevant restriction enzyme was used to digest 5 μL of the amplified products in a total reaction volume of 10 μL. The 100 base pair DNA ladder and the digestion products were resolved on 2.0% agarose gels stained with ethidium bromide and seen under a UV transilluminator (SYNGENE-InGeniusL). Gel photos of the ADIPOQ gene are shown in Figure 1

(a)

(b)

(c)

Figure 1

Genotypes for the ADIPOQ SNPs are as follows: (a) (rs266729), (b) (rs2241766), and (c) (rs1501299). In image (a), L1 stands for a 100 bp ladder; L3 stands for a wild genotype (250 bp); L2, L4, and L6 stand for heterozygous genotypes (250 bp, 137 bp, and 113 bp); and L5 for a mutant genotype (137 bp and 113 bp). In image (b), L1 denotes a 100 bp ladder; L2 denotes a wild genotype (305 bp); L4, L5, and L6 denote heterozygous genotypes (305 bp, 202 bp, and 103 bp); and L3 denote mutant genotypes (202 bp and 103 bp). In image (c), L1 stands for the 100 bp ladder; L6 stands for the wild genotypes (270 bp and 143 bp); L2, L4, L5, and L7 stand for the heterozygous genotypes (413 bp, 270 bp, and 143 bp); and L3 stands for the mutant genotype (413 bp).

3. Statistical Analysis

Statistical Package for Social Sciences (SPSS; Chicago, USA, version 20.0) was used for all statistical analyses. The one-sample Kolmogorov–Smirnov test was used to detect the normal distribution of data for baseline parameters. The Hardy–Weinberg equilibrium (HWE) was evaluated for all the SNPs in patients and controls by comparing the observed and expected frequencies of the genotypes using the chi-squared test. An independent t.test was used to analyze baseline parameters. The distribution of the genotypes and allele frequencies of ADIPOQ SNPs for patients and control were compared using the chi-squared test with two × two contingency tables using GraphPad Prism 6 software. The association of SNPs with other parameters was performed using the one-way ANOVA test. The association of the ADIPOQ SNPs with the risk of MetS was assessed by the odds ratio (OR) with 95% confidence intervals (CI) and logistic regression to predict risk factors. Linkage disequilibrium analysis of the three adiponectin gene SNP loci haplotypes was performed using SHEsis online software (http://analysis.bio-x.cn).

For all statistical tests for bilateral comparisons, ≤ 0.05 was considered statistically significant.

4. Results

Table 2 summarizes the clinical and biochemical characteristics of the participants. MetS patients showed substantially greater BMI, WC, SBP, and DBP when compared to non-MetS individuals . In addition, compared to non-MetS individuals, MetS patients had considerably higher HbA1c, serum TG, TC, and LDL-C levels while having significantly lower HDL-C levels. Genetic analysis showed that the ADIPOQ gene polymorphisms −11377C/G, +45T/G, and +276G/T were detected in all the participants. PCR products of C/G SNP (rs266729), T/G SNP (rs2241766), and G/T SNP (rs1501299) were 250 bp, 305 bp, and 413 bp, respectively (Figure 2). Restriction digestion was carried out following amplification. For the rs266729 genotype, the wild genotype (CC) produced a single band of 250 bp; the heterozygous genotype (CG) had three fragments of 250 bp, 137 bp, and 113 bp; and the homozygous mutant genotype (GG) produced two bands of 137 bp and 113 bp. For rs2241766, the wild genotype (TT) had a single band 305 bp; the heterozygous genotype (TG) produced three fragments 305 bp, 202 bp, and 103 bp; and the homozygous mutant genotype (GG) produced two bands 202 bp and 103 bp. For rs1501299, the wild genotype (GG) was digested and made two bands, 270 bp and 143 bp; the heterozygous genotype (GT) had three rounds, 413 bp, 270 bp, and 143 bp; and the homozygous mutant genotype produced a single band, 413 bp (Figure 1). Table 3 summarizes the genotypes and allele frequencies of ADIPOQ SNPs (rs266729, rs2241766, and rs1501299).

(a)

(b)

(c)

In the present study, the frequencies of mutant alleles −11377C/G (rs266729), +45T/G (rs2241766), and +276G/T (rs1501299) were considerably more significant in MetS participants (OR = 2.150, 2.293, and 2.228, respectively). Furthermore, one-way ANOVA and post hoc multiple comparison analysis of +45T/G (rs2241766) showed significantly higher serum triglycerides (TG), total cholesterol (TC), and LDL-C level in the GG genotype than in TT and TG genotypes. The +276G/T (rs1501299) increased the levels of SBP, serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein (LDL-C) in the TT genotype compared to GG and GT genotype, (Table 4). The relationship between the genotypes −11377C > G (rs266729), +45T > G (rs2241766), and +276G > T (rs1501299) and metabolic elements with the risk of MetS are listed in Table 5.

Using logistic regression univariate analysis, the significant risks of metabolic syndrome were hypertension, hyperglycemia, BMI, WC, serum TG, TC, LDL-C, HDL-C, ADIPOQ rs266729 (CG, GG), ADIPOQ rs2241766 (TG, GG), and ADIPOQ rs1501299 (GT, TT). However, it was found that hypertension, hyperglycemia, BMI, WC, serum TG, ADIPOQ rs2241766 (TG), and ADIPOQ rs1501299 (GT) can independently predict the occurrence of metabolic syndrome in healthy Sudanese adults when using multivariate logistic regression analysis. The distribution of the research population’s haplotype frequencies and linkage disequilibrium (LD) are displayed in Table 6. The three ADIPOQ SNPs (rs266729, rs2241766, and rs1501299) were associated with moderate LD levels (Dʹ = 0.54, 0.62, and 0.69, respectively). According to the LD measurements, CTT, CGG, and GTG haplotypes of 11377C > G, +45T > G, and +276G > T SNPs showed ORs 1.788, 1.622, and 1.641, respectively, with high risks towards MetS susceptibility.

5. Discussion

Metabolic syndrome (MetS) is a recognized risk factor for the onset of cardiovascular disease and other degenerative illnesses, which are the major causes of morbidity and mortality [2, 10, 11]. The adiponectin gene has been identified as a human adiposity marker after significant research into the relationships between genetic differences in the adiponectin gene and several obesity measurements and metabolic syndrome in numerous ethnic cultures [11]. This study was carried out to determine the relationship between the risk of MetS in the included studies and the polymorphisms in the ADIPOQ gene (SNP-11377C > G, SNP +45T > G, and SNP +276G > T). LD analysis revealed that the three loci rs266729, rs2241766, and rs1501299 were in a moderate LD block. For the first time, rs266729, rs2241766, and rs1501299 were discovered in a haplotype block and connected to MetS in Sudan. For the first time, all of our results point to the possibility that the haplotypes ADIPOQ CTT, CGG, GTG, CGT, and GTT were linked to MetS. Further, CTT was more significantly linked to MetS, and haplotype CTG is genetically protective against MetS. Additionally, in the Sudanese population, ADIPOQ-11377C > G (rs266729), +45T > G (rs2241766), and +276G > T (rs1501299) were all significantly linked with MetS. There were considerably more carriers of the CG and GG genotypes in the MetS group (22.8% and 6.2%) than in the non-MetS group (15.2% and 1.5%) in this study’s analysis of the genotype distribution of −11377C > G (rs266729) among MetS patients and non-MetS controls. It is also shown that the rs266729G allele raises the probability of developing metabolic syndrome in the research participants by 2.150 times . Our results are in line with a study by Garacia Robles et al. that suggests the minor allele G in the ADIPQ gene polymorphism rs266729 constitutes a risk factor for the development of MetS [10], and a study by Smetnev et al. that reports the SNP rs266729 of the ADIPOQ gene are significantly associated with cardiovascular and metabolic diseases [14].

Additionally, this study demonstrated a statistically significant difference in the genotype distribution of +45T > G (rs2241766) between MetS cases and non-MetS controls . There were significantly more carriers of the TG and GG genotypes in the MetS group (27.6% and 4.8%) than in the non-MetS group (16.2% and 1.0%). It is also discovered that the rs2241766G allele increases the risk of developing metabolic syndrome in the study participants by 2.293 folds . Our results are supported by research by Zahary et al. that indicates the genetic polymorphisms at the ADIPOQ +45T > G (rs2241766) loci enhanced the risk factor for the onset of MetS [15]. When looking at the relationship between the +276G > T (rs1501299) variation and MetS, it was shown that the T-minor allele contributed to a 2.228 fold increased risk of susceptibility to metabolic syndrome (MetS) in the current population. Our results are in line with research by Zahary et al., which suggests the genetic variants at the ADIPOQ +276G > T (rs1501299) loci enhanced the risk factor for developing MetS [15]. These significant associations persisted after the adjustments to hypertension, hyperglycemia, BMI, WC, serum TG, HDL-C, ADIPOQ rs2241766 (TG), and ADIPOQ rs1501299 (GT).

Moreover, our results are consistent with the information provided by Kaur et al. They demonstrated that the ADIPOQ +276G > T (rs1501299) polymorphism might be clinically useful in determining the risk of obesity and MetS [11]. The results of the current investigation showed that the mutant genotypes −11377C > G (rs266729), +45T > G (rs2241766), and +276 G> T (rs1501299) were not significantly associated with any of the obesity indices (BMI and WC). Our findings are in line with research by Ogundele et al. that found no correlation between +276G > T (rs1501299) and obesity indicators in the Nigerian population [8]. Our results, however, are the exact reverse of those obtained by Cui et al., who found a connection between central obesity and the ADIPOQ gene [7].

Furthermore, our study found no correlation between the genotypes of −11377C/G (rs266729), +45T/G (rs2241766), and +276G/T (rs1501299) and the risk factors for the metabolic syndrome (HbA1c, SBP, DBP, serum TG, TC, LDL-C, and HDL-C), except the +45T/G (rs2241766) which proofed to be higher in serum triglycerides (TG), total cholesterol (TC), and LDL-C in the GG genotype . Additionally, it showed that the +276G/T (rs1501299) SNP appeared to have higher SBP, serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein (LDL-C) in the TT genotype .

From another point of view, it is critical to assess if the polymorphisms affect the alteration of MetS components and other obesity-related disorders following a change in lifestyle, such as dieting. De Luis et al. demonstrated that in this situation the CC genotype of the ADIPQ-11377C > G polymorphism is connected to increase in adiponectin levels and decrease in total cholesterol, LDL-C, glucose, and insulin levels as well as the homeostasis model assessment for insulin resistance after weight loss [16]. All parameters showed the same improvement after a diet high in polyunsaturated fat [17]. One interventional study of 60 severely obese patients evaluated 32 months after bariatric surgery revealed that C-allele homozygotes decreased BMI and the lipid profile in obese people [18].

Our haplotype analysis revealed that the MetS participants had significantly higher frequencies of the CTT, CGG, GTG, CGT, and GTT haplotypes. The results of the association analysis revealed that the CTT, CGG, GTG, CGT, and GTT haplotypes increased the risk of developing the metabolic syndrome in the research participants by 1.788 , 1.622 , 1.641 , 5.863 , and 5.621 times, respectively.

The current case-control study has both strengths and limitations. To the best of our knowledge, this is the first study in Sudan to provide information on the genetic relationship between ADIPOQ variants and susceptibility to the metabolic syndrome risk. The study gathered enough information about lifestyle choices that might be confounding factors in the onset of disease. These variables may also play a role in figuring out how genes and the environment interact.

One limitation of the current study was that no SNPs with proven relationships published in the literature were genotyped due to cost-effectiveness concerns. Based on information from the literature search and their higher allele frequency in the SNP database, the SNPs for the current study were selected.

In conclusion, the results of this study give strong support for the hypothesis that the metabolic syndrome risk in the Sudanese population is strongly influenced by the ADIPOQ-11377C > G (rs266729), +45T > G (rs2241766), and +276G > T (rs1501299) polymorphisms and their haplotype combinations. Given the significance of gene-gene interactions, more studies are required to determine the substantial contributions of ADIPOQ gene variants to the emergence of obesity and other characteristics of metabolic diseases to clarify the pathological processes.

Data Availability

The datasets used and/or analyzed during the current study can be found at the following link: https://figshare.com/articles/dataset/ADIPOQ_gene_data/21687407.

Ethical Approval

Ethical approval was obtained before the start of the study from the Ethics Committee of the Sudan University of Science and Technology (no. DSR-IEC-04-08). All the procedures used in this study met the current guidelines of the Helsinki Declaration.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors express our gratitude to all of our collaborators and workers who made this study possible. Additionally, the authors would like to thank their colleagues from the Neurological Science Center-Khartoum State research laboratory, whose insight and experience benefited the research.

References

S. P. Palit, R. Patel, S. D. Jadeja et al., “A genetic analysis identifies a haplotype at adiponectin locus: association with obesity and type 2 diabetes,” Scientific Reports, vol. 10, no. 1, p. 2904, 2020.
View at: Publisher Site | Google Scholar
U. Zafar, S. Khaliq, H. U. Ahmad, S. Manzoor, and K. P. Lone, “Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links,” Hormones, vol. 17, no. 3, pp. 299–313, 2018.
View at: Publisher Site | Google Scholar
K. Selvi, B. Shanthi, and P. Karam, “Study of lipid profile in metabolic syndrome patients,” Journal of Pharmaceutical Research International, vol. 32, no. 13, pp. 166–173, 2020.
View at: Publisher Site | Google Scholar
H. E. Yasir, O. A. Tahir, B. M. Leena, and S. N. Imam, “Metabolic syndrome and its association with obesity and lifestyle factors in Sudanese population,” Diabetes and Metabolic Syndrome: Clinical Research Reviews, vol. 10, no. 3, pp. 128–131, 2016.
View at: Publisher Site | Google Scholar
M. Alimi, M. T. Goodarzi, and M. Nekoei, “Adiponectin gene polymorphisms and risk of type 2 diabetes: an updated evidence for meta-analysis,” Diabetology and Metabolic Syndrome, vol. 13, no. 1, p. 133, 2021.
View at: Publisher Site | Google Scholar
J. S. Kanu, S. Qiu, Y. Cheng et al., “Associations between three common single nucleotide polymorphisms (rs266729, rs2241766, and rs1501299) of ADIPOQ and cardiovascular disease: a meta-analysis,” Lipids in Health and Disease, vol. 17, no. 1, p. 126, 2018.
View at: Publisher Site | Google Scholar
M. Cui, Y. Gao, Y. Zhao et al., “Association between adiponectin gene polymorphism and environmental risk factors of type 2 diabetes mellitus among the Chinese population in hohhot,” BioMed Research International, vol. 2020, Article ID 6383906, 9 pages, 2020.
View at: Publisher Site | Google Scholar
O. E. Ogundele, K. O. Adekoya, A. A. A. Osinubi, A. A. Awofala, and B. O. Oboh, “Association of adiponectin gene (ADIPOQ) polymorphisms with measures of obesity in Nigerian young adults,” Egyptian Journal of Medical Human Genetics, vol. 19, no. 2, pp. 123–127, 2018.
View at: Publisher Site | Google Scholar
Y. Dong, G. Huang, X. Wang, Z. Chu, J. Miao, and H. Zhou, “Meta-analysis of the association between adiponectin SNP 45, SNP 276, and type 2 diabetes mellitus,” PLoS One, vol. 15, no. 10, 2020.
View at: Publisher Site | Google Scholar
M. J. Garcia Robles, J. Camarillo Alba, M. D J. Valenzuela Gurrola, J. A. Lopez, and S. Ramirez-De Los Santos, “ADIPQ gene polymorphism rs266729 (-11377 C>G) and metabolic syndrome risk in a Mexican population of western Mexico,” Nutricion Hospitalaria, vol. 38, no. 1, pp. 67–72, 2021.
View at: Publisher Site | Google Scholar
H. Kaur, B. Badaruddoza, V. Bains, and A. Kaur, “Genetic association of ADIPOQ gene variants (-3971A>G and +276G>T) with obesity and metabolic syndrome in North Indian Punjabi population,” PLoS One, vol. 13, no. 9, 2018.
View at: Publisher Site | Google Scholar
Z. Gu, P. Zhu, Q. Wang et al., “Obesity and lipid-related parameters for predicting metabolic syndrome in Chinese elderly population,” Lipids in Health and Disease, vol. 17, no. 1, p. 289, 2018.
View at: Publisher Site | Google Scholar
A. Gassoum, M. A. Arbab, S. A. Aldeaf, L. A. Elhassan, E. Elshibli, and A. M. Elhassan, “Allele frequency of P53 gene Arg72Pro in Sudanese meningioma patients and controls,” International Journal of Scientific and Technology Research, vol. 3, no. 6, pp. 243–248, 2014.
View at: Google Scholar
K. Smetnev, K. Kutsenko, K. Gumanova et al., “Associations of SNPs of the ADIPOQ gene with serum adiponectin levels, unstable angina, and coronary artery disease,” Biomolecules, vol. 9, no. 10, p. 537, 2019.
View at: Publisher Site | Google Scholar
M. N. Zahary, N. S. Harun, N. Ridzwan et al., “Increased risk of metabolic syndrome with genetic polymorphism of ADIPOQ among a Temiar population in Malaysia,” Meta Gene, vol. 24, Article ID 100653, 2020.
View at: Publisher Site | Google Scholar
D. A. de Luis, D. Primo, O. Izaola et al., “Role of the variant in adiponectin gene rs266729 on weight loss and cardiovascular risk factors after a hypocaloric diet with the Mediterranean pattern,” Nutrition, vol. 60, pp. 1–5, 2019.
View at: Publisher Site | Google Scholar
D. A. de Luis, D. Primo, O. Izaola, and R. Aller, “Effect of two different dietary fatty acid profiles and variant rs266729 in ADIPOQ on weight loss and adiponectin concentrations,” Endocrinologia, diabetes y nutricion., vol. 67, no. 6, pp. 374–382, 2020.
View at: Publisher Site | Google Scholar
A. S. Gasparotto, D. O. Borges, M. R. Zandoná, M. J. Ramos, N. G. Meihnardt, and V. S. Mattevi, “Adiponectin promoter polymorphisms are predictors of lipid profile improvement after bariatric surgery,” Genetics and Molecular Biology, vol. 40, no. 4, pp. 736–742, 2017.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Altaf S. Mosad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

326

Downloads

265

Citations